Skip to main content
  • Sapien TAVR Devices Win Expanded Indication May now be used in intermediate-risk patients

    The FDA approved an expanded indication for the Sapien XT and Sapien 3 transcatheter aortic valve replacement (TAVR) systems, making them available to patients at intermediate surgical risk.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details